Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

Undergraduate Research Showcase

Undergraduate research is the exploration of a specific topic within a field by an undergraduate student that makes an original contribution to the discipline.

Epidermal Growth Factor Receptor Gene Mutations

Biography

Sydney StraderMy name is Sydney Strader and I am a sophomore at Valencia and will be transferring to the University of Central Florida this upcoming fall. I am interested in pursuing a career in medicine and specifically interested in research regarding preventative healthcare and personalized medical treatments.

Presentation

ABSTRACT:  The epidermal growth factor receptor (EGFR) is a protein that controls cell growth and division. The EGFR can be overactivated in cancer patients, causing cells to grow and divide too quickly. The drug erlotinib has produced a significant response in inhibiting EGFR growth  in patients who have been diagnosed with malignant glioma. Studies show that 8 out of 41 glioma patients had beneficial results due to Erlotinib. The study concluded that  patients with different mutations may not have the same benefit as others. Patients with an EGFR-L861Q mutation were not as likely as those with EGFR mutations L858R and G719S to respond to the drug. It is currently undetermined what characteristics of these mutations make it more receptive to erlotinib than others. The aim of this study is to find these properties by comparing the amino acid sequences of the different EGFR mutations and wild-type to find characteristics that contribute to a more beneficial response to Erlotinib. Preliminary research shows differences between the three mutations in: hydrophobic residues, buried uncharged residue replacements, the presence of hydrogen bonds, cavity contractions or expansions, and exposed or buried residues. The data may suggest that these differences contribute to the difference in receptiveness of the drug erlotinib in cancer patients between the variant mutations.

Discussion

Click on the Discussion tab or follow this link to join the discussion.

Faculty Mentor

Rita Luther

Professor of Biology

East Campus

rluther1@mail.valenciacollege.edu

 

 

The Valencia College libraries do not welcome solicitation of resources to be added to our LibGuides. This includes but is not limited to vendors, search engine optimizers, placement of ads, products, or any other requests. Our LibGuides are carefully curated resources developed in partnership with faculty, staff, and students to support specific assignments, courses, events, and other related purposes at Valencia College. The Valencia libraries reserve the right to ignore LibGuide resource solicitations, and/or block persistent requests from groups or individuals to add or promote links in our LibGuides.